Evidence map›Paper›PMID 37713103›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2023

Probiotic for Pancreatic β-Cell Function in Type 2 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.

Maryana Savytska, Dmytro Kyriienko, Iuliia Komisarenko, Oleksandr Kovalchuk, Tetyana Falalyeyeva, Nazarii Kobyliak

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05765292 (Efficacy and Safety of Multi-strain Probiotic on Pancreatic β-cell Function in Type 2 Diabetes Patients), which is not on this map. Cited by 16 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 6 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05765292 nacompletednot on this map

Efficacy and Safety of Multi-strain Probiotic on Pancreatic β-cell Function in Type 2 Diabetes Patients

TypeinterventionalSponsorBogomolets National Medical UniversityRan2021 to 2021Enrolled68ConditionsType2 Diabetes, Obesity, Insulin Resistance, Obesity, AbdominalArmsProbiotic, Placebo
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 6 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Review
  12. Review
  13. Article
  14. Beneficial Effects of ProbioticInternational journal of molecular sciences · 2024
    Article
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Maryana SavytskaNormal Physiology Department, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
Dmytro KyriienkoKyiv City Clinical Endocrinology Center, Kyiv, Ukraine.
Iuliia KomisarenkoEndocrinology Department, Bogomolets National Medical University, Kyiv, Ukraine.
Oleksandr KovalchukTaras Shevchenko National University of Kyiv, Kyiv, Ukraine.
Tetyana FalalyeyevaTaras Shevchenko National University of Kyiv, Kyiv, Ukraine.
Nazarii KobyliakEndocrinology Department, Bogomolets National Medical University, Kyiv, Ukraine. nazariikobyliak@gmail.com.ORCID http://orcid.org/0000-0001-9814-689X
Taras Shevchenko National University of Kyiv · UABogomolets National Medical University · UADanylo Halytsky Lviv National Medical University · UAKyiv City Clinical Oncology Center · UAKyiv National University of Technologies and Design · UA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMany clinical studies have proved the effectiveness of probiotics in metabolic disorders associated with insulin resistance. However, the impact of probiotic therapy on pancreatic β-cell function is ambiguous. The influence of probiotic supplementation vs. placebo on β-cell function in people with type 2 diabetes (T2D) was assessed in a double-blind, single-center, randomized, placebo-controlled trial (RCT).

methodsSixty-eight patients with T2D were selected for participation in the RCT. Patients were randomly allocated to consumption of live multistrain probiotics or a placebo for 8 weeks, administered as a sachet formulation in double-blind treatment. The primary main outcome was the assessment of β-cell function as change in C-peptide and HOMA-β (homeostasis model assessment-estimated β-cell function), which was calculated using the HOMA2 calculator (Diabetes Trials Unit, University of Oxford). Secondary outcomes were the changes in glycemic control-related parameters, anthropomorphic variables, and cytokines levels. Analysis of covariance was used to assess the difference between groups.

resultsSupplementation with live multiprobiotic was associated with slight significant improvement of β-cell function (HOMA-β increased from 32.48 ± 13.12 to 45.71 ± 25.18; p = 0.003) and reduction of fasting glucose level (13.03 ± 3.46 vs 10.66 ± 2.63 mmol/L and 234.63 ± 62.36 vs 192.07 ± 47.46 mg/dL; p < 0.001) and HbA1c (8.86 ± 1.28 vs 8.48 ± 1.22; p = 0.043) as compared to placebo. Probiotic therapy significantly affects chronic systemic inflammation in people with T2D by reducing pro-inflammatory cytokine levels.

conclusionsProbiotic therapies modestly improved β-cell function in patients with T2D. Modulating the gut microbiota represents a new diabetes treatment and should be tested in more extensive studies.

trial registrationNCT05765292.

Indexed as

Gut microbiotaInsulin resistancePancreatic β-cellsProbioticsType 2 diabetes

Identifiers

PMID37713103
PMCPMC10570251
OpenAlexW4386758024

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.